Overview


According to FutureWise analysis the market for late stage chronic kidney disease therapeutics in 2023 is US$ 7.35 billion, and is expected to reach US$ 17.96 billion by 2031 at a CAGR of 11.82%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Late Stage Chronic Kidney Disease Therapeutics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Late Stage Chronic Kidney Disease Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • AbbVie
  • Amgen
  • Ardelyx
  • AstraZeneca
  • Deltanoid
  • Genzyme
  • Keryx
  • Kyowa Hakko Kirin
  • Mitsubishi Tanabe
  • OPKO Health
  • Relypsa
  • Sanofi
  • Shield Therapeutics
  • Shire
  • Spectrum
  • Vifor
  • ZS Pharma

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Calcimimetics
  • Sensipar (cinacalcet hydrochloride)
  • Vitamin D Sterols
  • Nutritional/Native Vitamin D
  • Vitamin D Receptor Agonists
  • Phosphate Binders
    • Calcium-Based Phosphate Binders
    • Aluminum-Containing Phosphate Binders
    • Magnesium-Containing Phosphate Binders
  • Renvela/Renagel
  • Fosrenol (lanthanum carbonate)
  • Velphoro (sucroferric oxyhydroxide)
  • Auryxia (ferric citrate)
  • Potassium Binders
  • Resins
  • Veltassa (patiromer sorbitex calcium)

By Indication

  • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • Late Stage Chronic Kidney Disease Induced Hyperkalemia

By End user

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Late Stage Chronic Kidney Disease Therapeutics Market By Product Type, By Indication, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Late Stage Chronic Kidney Disease Therapeutics Market Variables, Trends & Scope

    •         1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Late Stage Chronic Kidney Disease Therapeutics Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Late Stage Chronic Kidney Disease Therapeutics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Late Stage Chronic Kidney Disease Therapeutics Market, By Product Type Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Calcimimetics
        2. Sensipar (cinacalcet hydrochloride)
        3. Vitamin D Sterols
        4. Nutritional/Native Vitamin D
        5. Vitamin D Receptor Agonists
        6. Phosphate Binders
         6.1. Calcium-Based Phosphate Binders
         6.2. Aluminum-Containing Phosphate Binders
         6.3. Magnesium-Containing Phosphate Binders
        7. Renvela/Renagel
        8. Fosrenol (lanthanum carbonate)
        9. Velphoro (sucroferric oxyhydroxide)
        10. Auryxia (ferric citrate)
        11. Potassium Binders
        12. Resins
        13. Veltassa (patiromer sorbitex calcium)

  • 8.   Global Late Stage Chronic Kidney Disease Therapeutics Market, By Indication Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
        2. Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
        3. Late Stage Chronic Kidney Disease Induced Hyperkalemia

  • 9.   Global Late Stage Chronic Kidney Disease Therapeutics Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)

    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Mail Order Pharmacy

  • 10.   North America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 11.   Latin America Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 12.   Europe Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 13.   Asia Pacific Late Stage Chronic Kidney Disease Therapeutics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 14.   Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
         2.1. Saudi Arabia
         2.2. UAE
         2.3. South Africa
         2.4. Egypt
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. AbbVie
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Amgen
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Ardelyx
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AstraZeneca
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Deltanoid
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Genzyme
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Keryx
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Kyowa Hakko Kirin
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Mitsubishi Tanabe
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. OPKO Health
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Relypsa
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Sanofi
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Shield Therapeutics
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Shire
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Spectrum
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Vifor
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. ZS Pharma
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11